Response to oral 5-AZA and ROMI across study subpopulations
| Response type . | All patients (N = 31), n (%) . | Phase 1 population (n = 26), n (%) . | Expansion cohort (n = 5), n (%) . | Non–T-cell lymphoma (n = 20), n (%) . | T-cell lymphoma (n = 11), n (%) . |
|---|---|---|---|---|---|
| Overall response | 10 (32) | 6 (23) | 4 (80) | 2 (10) | 8 (73) |
| Complete response | 7 (23) | 3 (12) | 4 (80) | 1 (5) | 6 (55) |
| Partial response | 3 (10) | 3 (12) | 0 | 1 (5) | 2 (18) |
| Stable disease | 7 (23) | 7 (27) | 0 | 7 (35) | 0 |
| Progressive disease | 11 (35) | 10 (38) | 1 (20) | 9 (45) | 2 (18) |
| Not evaluable | 3 (10) | 3 (12) | 0 | 2 (10) | 1 (9) |
| Response type . | All patients (N = 31), n (%) . | Phase 1 population (n = 26), n (%) . | Expansion cohort (n = 5), n (%) . | Non–T-cell lymphoma (n = 20), n (%) . | T-cell lymphoma (n = 11), n (%) . |
|---|---|---|---|---|---|
| Overall response | 10 (32) | 6 (23) | 4 (80) | 2 (10) | 8 (73) |
| Complete response | 7 (23) | 3 (12) | 4 (80) | 1 (5) | 6 (55) |
| Partial response | 3 (10) | 3 (12) | 0 | 1 (5) | 2 (18) |
| Stable disease | 7 (23) | 7 (27) | 0 | 7 (35) | 0 |
| Progressive disease | 11 (35) | 10 (38) | 1 (20) | 9 (45) | 2 (18) |
| Not evaluable | 3 (10) | 3 (12) | 0 | 2 (10) | 1 (9) |